tiprankstipranks
Appeals court sides with Amneal over Teva in inhaler patent fight
The Fly

Appeals court sides with Amneal over Teva in inhaler patent fight

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision that would remove patents related to Teva Pharmaceuticals’ (TEVA) ProAir HFA inhaler from the Food and Drug Administration’s Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on the FDA list. The order posted to the site of the court states: “Teva appealed, and we stayed the district court’s order pending our resolution of this case. We now lift the stay and affirm the district court’s delisting order.”

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App